Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis

Alemtuzumab (previously known as Campath(®)) is a humanized monoclonal antibody directed against the CD52 antigen on mature lymphocytes that results in lymphopenia and subsequent modification of the immune repertoire. Here we explore evidence for its efficacy and safety in relapsing-remitting multip...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drug design, development and therapy Jg. 7; S. 131 - 138
Hauptverfasser:	Brown, William, Coles, Alasdair
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	New Zealand Dove Medical Press Limited 01.01.2013 Taylor & Francis Ltd Dove Press Dove Medical Press
Schlagworte:	Adjuvants, Immunologic - adverse effects Adjuvants, Immunologic - therapeutic use Alemtuzumab Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - immunology Antibodies, Monoclonal, Humanized - therapeutic use Antigens, CD - immunology Antigens, Neoplasm - immunology Atrophy Autoimmunity Brain Campath CD52 Antigen Clinical trials Drug therapy efficacy Glycoproteins - immunology Hemorrhage Humans Immunotherapy Interferon Interferon beta-1a Interferon-beta - adverse effects Interferon-beta - pharmacology Interferon-beta - therapeutic use Lymphocytes Lymphopenia Monoclonal antibodies Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - immunology Multiple Sclerosis, Relapsing-Remitting - physiopathology Patients Pharmaceutical research Purpura relapsing-remitting multiple sclerosis Review Therapy Thrombocytopenic purpura Thyroid Treatment Outcome relapsing–remitting multiple sclerosis alemtuzumab efficacy Campath
ISSN:	1177-8881, 1177-8881
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!